SNES

SenesTechB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-11

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

22%

Probability

Target price

$2.10

+21.4% vs current

Most likely

Base case

51%

Probability

Target price

$1.55

-10.4% vs current

B-

Bear case

27%

Probability

Target price

$0.75

-56.6% vs current

AI sentiment snapshot

Latest data as of 2026-05-07

AI commentary

Primary-source tone is cautiously constructive, but the setup remains a low-conviction monitoring story. Deterministic scores remain only modestly positive with high uncertainty, catalyst density is sparse, and company-source flow since the March 12-13, 2026 earnings/10-K window has been thin. The peer set is also a material weakness: direct operating comps are private, while available public names are loose sector screens. At the May 6, 2026 anchor price of $1.47, the market appears to be discounting dilution and execution risk more than a near-term re-rating.

RankAlpha Sentiment Codex - 2026-05-07

Open full AI memo

Evidence flagged

Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.

Impact

tentative

Confidence

AI events

2026-08-15catalystAmazon transition normalization and e-commerce mix recoveryHigh impact

Management said 2025 revenue rose 20% to $2.2 million, e-commerce revenue increased 88%, and the shift to direct Amazon management caused an estimated $200,000 revenue hit that should reverse only if integration stabilizes; margin expansion also depends on that recovery [#8-K-2026-03-12].

2026-09-30eventCEO search outcome and go-to-market continuityHigh impact

The board started a formal CEO search after Joel Fruendt's retirement and appointed Dr. Jamie Bechtel as Interim Executive Chair, so a permanent appointment or strategy change could alter execution expectations [#8-K-2026-03-12].

2027-06-30catalystCash runway durability versus earlier-than-expected financingHigh impact

The 10-K said cash, cash equivalents, and short-term investments were $8.6 million at December 31, 2025 and management expects funding through approximately the second quarter of 2027, but also said weaker revenue growth or higher expenses could force financing sooner [#10-K-2026-03-13].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-07 • Updated nightlySource: Internal modelMethodology